F128 - Dermatologic Side Effects of Anticancer Drugs in 2018: What You Need to Know
Monday, February 19; 1:00 PM - 3:00 PM
Following this course, the attendee should be able to:
- Diagnose the most common and clinically significant dermatologic adverse events of new cancer therapies.
- Develop preventive and treatment strategies for skin, hair, and nail events to novel oncology agents.
- Summarize the efficacy of interventions that mitigate adverse events in oncology.
Of the 1.7 million people diagnosed with cancer every year, approximately 65% will receive a systemic treatment, including cytotoxic, targeted, or immunotherapeutic agent. These will frequently result in toxicities such as alopecia, rash, pruritus, and nail toxicities, all of which affect quality of life and the ability to receive life-saving or prolonging therapies. This session provides critical knowledge to diagnose, prevent, and treat dermatologic adverse events from novel anticancer agents.
- Albert, Denise: no financial relationships exist with commercial interests.
- Lacouture, Mario E., MD: AbbVie – C(H); ADC Therapeutics – C(H); Adgero Biopharmaceuticals Holdings, Inc. – C(H); Astellas Pharma US, Inc – C(H); Celldex – C(H); Galderma Research & Development, LLC – C(H); Harborside – O(Fees); Helsinn Healthcare – C(H); Johnson and Johnson – C(H); Lindiskin – C(H); Menlo Therapeutics – C(H); Merck & Co., Inc – C(H); Novartis – C(H); Novocure – C(H); Wiley & Sons, Inc. – O(Fees);
- Larocca, Cecilia, MD: no financial relationships exist with commercial interests.
- LeBoeuf, Nicole, MD: Bayer – Speaker/Faculty Education(H);
Monday, February 19
Dr. Lacouture / Supportive Oncodermatology
Dr. LeBoeuf / Targeted Therapy
Dr. Wu / Immune Checkpoint Inhibitors
Dr. Lacouture / Scalp cooling and hair disorders